clinical trial · NCT06496568
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche·phase1·recruiting·n = 30
PIK3CA-Mutated CancersInavolisibAtezolizumabPembrolizumab
brief summary
The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent, in combination with atezolizumab, and in combination with pembrolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, including previously treated head and neck squamous cell carcinoma (HNSCC).
started
Dec 11, 2023
primary completion
Sep 28, 2028
completion
Sep 28, 2028
last updated
Apr 16, 2026
official title
A Phase I/Ib Study Evaluating Single-Agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol